Irritable Bowel Syndrome Market Overview
The Irritable Bowel Syndrome market is undergoing a significant transformation as new therapeutic approaches, growing disease awareness, and robust pipeline activity continue to reshape the treatment landscape. According to DelveInsight’s analysis, the irritable bowel syndrome market is expected to grow substantially during the forecast period, fueled by an expanding patient pool, unmet clinical needs, and the emergence of novel biologic and small molecule therapies.
Irritable bowel syndrome (IBS) is a multifactorial gastrointestinal condition involving motility dysfunction, visceral hypersensitivity, psychiatric comorbidity, neuroendocrine dysfunction, genetic and epigenetic factors, dietary influences, and immune activation. Approximately 32 million cases of irritable bowel syndrome were reported across the 7 Major Markets (7MM) in 2023, with the United States alone accounting for nearly 46% of total prevalent cases – underscoring the massive clinical and economic burden this condition places on the healthcare system.
The condition is more prevalent in younger populations under 35 years of age compared to older age groups and disproportionately affects women over men. Among diagnosed cases, approximately 89% fall under the moderate-to-severe category, while the remaining 11% are classified as mild. In terms of clinical subtype, diarrhea-predominant IBS (IBS-D) is the most common, accounting for approximately 35% of the diagnosed patient pool, followed by mixed stool pattern (IBS-M), constipation-predominant (IBS-C), and unspecified (IBS-U) subtypes.
Key Companies Operating in the Irritable Bowel Syndrome Market
Some of the key Irritable Bowel Syndrome companies working in the Irritable Bowel Syndrome market are RedHill Biopharma, Forest Pharmaceuticals, Inc., Bausch Health, Ironwood Pharmaceuticals, AbbVie, Astellas Pharma, ANI Pharmaceuticals, Amneal Pharmaceuticals, 4D Pharma, and others. These organizations are actively engaged in developing, commercializing, and refining therapies across both the marketed and investigational segments of the IBS landscape.
Irritable Bowel Syndrome Epidemiology
The epidemiological profile of irritable bowel syndrome presents a compelling picture of an undertreated yet widespread condition. According to Irritable Bowel Syndrome market research, IBS affects approximately 5% of the global population – roughly 1 in every 20 people in the United States. Prevalence rates across the 7MM, as per ROME IV criteria, are as follows: the United States at 5.3%, Germany at 3.7%, France at 4.2%, Italy at 5%, Spain at 4.2%, the United Kingdom at 4%, and Japan at 2.2%.
The gender disparity in IBS is notable. In the United States alone, approximately 9.7 million female patients were diagnosed with irritable bowel syndrome in 2023, compared to approximately 4.9 million male patients. Severity distribution further illustrates the clinical burden – approximately 48% of diagnosed prevalent cases belong to the severe category, while 41% are moderate and 11% are mild.
The IBS epidemiology chapter in DelveInsight’s report provides historical and forecasted data segmented by prevalent cases, diagnosed prevalence, gender-specific cases, age-specific cases, severity-specific cases, subtype-specific cases, and treated cases across the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.
Marketed Irritable Bowel Syndrome Drugs
The currently approved drug armamentarium for IBS includes several key therapies addressing both diarrhea- and constipation-predominant subtypes:
- VIBERZI/TRUBERZI (eluxadoline) – AbbVie
Eluxadoline is a novel class of medication that acts locally on receptors within the gastrointestinal tract. It improves diarrhea and abdominal pain by interacting with mu- and delta opioid receptors in the intestine. Activation of the mu-receptor reduces diarrhea, while antagonism of the delta-receptor enhances analgesic activity and reduces the risk of constipation. VIBERZI acts within the enteric nervous system and is available in tablet form for oral administration in adults with IBS-D.
- LINZESS/CONSTELLA (linaclotide) – Ironwood Pharmaceuticals/AbbVie/Astellas Pharma
Linaclotide is a guanylate cyclase-C agonist that binds to its receptor locally within the intestinal epithelium, resulting in increased intestinal fluid secretion, accelerated gastrointestinal transit, and reduced activity of pain-sensing nerves in the intestine. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for adults with IBS-C, while in Europe, AbbVie markets the molecule as CONSTELLA for moderate-to-severe IBS-C. Notably, LINZESS garnered approximately USD 600 million in revenue and received FDA approval in 2023 for functional constipation in pediatric patients – a milestone expected to position it as a blockbuster drug by the end of the decade.
Other approved therapies include XIFAXAN (rifaximin), IBSRELA (tenapanor), and TRULANCE (plecanatide). Historically, laxatives, antidiarrheals, antispasmodics, and antidepressants – alongside dietary and lifestyle modifications – have formed the backbone of IBS management, with laxatives generating the highest sales in 2023.
Despite this array of options, approximately 60% of patients are still managed through non-conventional treatments, owing to persistent dissatisfaction with the efficacy and safety profiles of available prescription drugs. This gap remains the single most significant driver of innovation in the Irritable Bowel Syndrome market trends today.
Emerging Irritable Bowel Syndrome Drugs
The IBS pipeline reflects a dynamic and increasingly differentiated landscape, with biologics and novel small molecules gaining strong momentum.
- BEKINDA (RHB-102) – RedHill Biopharma
RHB-102 is an investigational, once-daily, bi-modal release oral formulation of ondansetron – a 5-HT3 serotonin receptor inhibitor intended to treat nausea, vomiting, and diarrhea in patients with acute gastroenteritis, gastritis, and IBS-D. RedHill Biopharma has completed a Phase II clinical trial (NCT02757105) evaluating RHB-102 in patients with diarrhea-predominant IBS.
- Blautix (MRx1234) – 4D Pharma
Blautix is a single-strain live biotherapeutic product (LBP) designed to treat both IBS-C and IBS-D, making it potentially the first-ever disease-modifying therapy suitable for all IBS patients regardless of clinical subtype. Its unique metabolic activity – consuming hydrogen and producing acetate – promotes bacterial cross-feeding within the gut microbiota, increasing microbial diversity and stability, attributes notably diminished in IBS patients versus healthy controls. A Phase II clinical trial (NCT03721107) has been completed evaluating Blautix in adults with IBS-C or IBS-D.
Other emerging therapies include Rifamycin (small molecule) and Aldafermin (biologic). Biologics are anticipated to be a particularly promising class for IBS management in the forthcoming years, with the potential to address disease mechanisms at a more fundamental level than current symptomatic treatments.
Recent Developments in the Irritable Bowel Syndrome Market
Key recent milestones shaping Irritable Bowel Syndrome market insight include:
- In Jan 2025, the FDA granted tentative approval to Amneal Pharmaceuticals’ 550 mg rifaximin tablets, referencing Bausch Health’s Xifaxan, for the treatment of adults with IBS-D.
- In Dec 2024, ANI Pharmaceuticals announced the commercial launch of Prucalopride Tablets following receipt of final FDA approval for its Abbreviated New Drug Application (ANDA). These tablets serve as the generic version of Motegrity®.
Conclusion
The irritable bowel syndrome landscape is at an inflection point. With a large and growing patient population, an expanding portfolio of approved therapies, and an energetic development pipeline anchored by biologics and precision small molecules, the road ahead offers considerable promise. Regulatory milestones such as pediatric approvals and generic launches are reshaping competitive dynamics, while unmet needs continue to inspire innovation. Stakeholders across the pharmaceutical and clinical spectrum would do well to closely monitor evolving Irritable Bowel Syndrome market trends as the decade unfolds, given the scale of the opportunity and the pace of change already underway.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
